Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
37.38
-0.10 (-0.27%)
Feb 4, 2026, 1:02 PM EST - Market open
HRMY Employees
Harmony Biosciences Holdings had 268 employees as of December 31, 2024. The number of employees increased by 22 or 8.94% compared to the previous year.
Employees
268
Change (1Y)
22
Growth (1Y)
8.94%
Revenue / Employee
$3,081,881
Profits / Employee
$692,821
Market Cap
2.15B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 268 | 22 | 8.94% |
| Dec 31, 2023 | 246 | 46 | 23.00% |
| Dec 31, 2022 | 200 | 20 | 11.11% |
| Dec 31, 2021 | 180 | 30 | 20.00% |
| Dec 31, 2020 | 150 | 0 | - |
| Sep 30, 2020 | 150 | 0 | - |
| Jun 30, 2020 | 150 | - | - |
| Mar 31, 2020 | 150 | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 1,372 |
| Recursion Pharmaceuticals | 800 |
| Ascentage Pharma Group International | 605 |
| Galapagos NV | 558 |
| Nuvation Bio | 291 |
| Aurinia Pharmaceuticals | 130 |
| Olema Pharmaceuticals | 122 |
| Mesoblast | 81 |
HRMY News
- 21 days ago - Harmony Biosciences Holdings, Inc. (HRMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 23 days ago - Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation - Business Wire
- 4 weeks ago - Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG - GlobeNewsWire
- 2 months ago - Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome - Business Wire
- 2 months ago - Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting - Business Wire
- 2 months ago - Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation - Business Wire
- 2 months ago - Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence - Business Wire